A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
Latest Information Update: 15 Sep 2023
At a glance
- Drugs RIST 4721 (Primary)
- Indications Palmoplantar pustulosis
- Focus Therapeutic Use
- Sponsors Aristea Therapeutics
- 10 Feb 2023 Status changed from active, no longer recruiting to discontinued, according to an Aristea Therapeutics media release.
- 10 Feb 2023 According to an Aristea Therapeutics media release, due to safety findings in the ongoing phase trials, the company has discontinued the RIST4721 development program in order to protect patient safety. The Board of Directors has determined after careful and extensive consideration of a range of strategic alternatives, that the appropriate business decision is to undertake an orderly conclusion of the Aristea Therapeutics business and operations and dissolve the company.
- 10 Feb 2023 Status changed from recruiting to active, no longer recruiting.